ArriVent BioPharma, Inc. Common Stock

NasdaqGM AVBP

ArriVent BioPharma, Inc. Common Stock EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024

ArriVent BioPharma, Inc. Common Stock EBITDA Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
NasdaqGM: AVBP

ArriVent BioPharma, Inc. Common Stock

CEO Dr. Zhengbin Yao Ph.D.
IPO Date Jan. 26, 2024
Location United States
Headquarters 18 Campus Boulevard
Employees 40
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

StockViz Staff

January 15, 2025

Any question? Send us an email